{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:15:28Z","timestamp":1740147328667,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Trauma Emerg Surg"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To investigate the effect of antithrombotics on the occurrence of maxillofacial haemorrhagic symptoms, and to determine if these haemorrhagic symptoms are predictors of maxillofacial fractures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>A prospective cohort study was conducted of consecutive patients with maxillofacial trauma who had been admitted to the emergency department of four hospitals in the Netherlands. This study compared five haemorrhagic symptoms (peri-orbital haematoma, raccoon eyes, epistaxis, subconjunctival ecchymosis, and intra-oral haematoma) between patients not-using (NUA) and using (UA) of antithrombotics, and whether these maxillofacial haemorrhagic symptoms served as predictors for maxillofacial fractures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of the 1005 patients, 812 (81%) belonged to the NUA group, and 193 (19%) to the UA group. UA patients exhibited higher frequencies of peri-orbital hematoma (54% vs. 39%, p\u2009&lt;\u20090.001), raccoon eyes (10% vs. 5%, p\u2009=\u20090.01), and subconjunctival ecchymoses (16% vs. 7%, p\u2009&lt;\u20090.001). In NUA, peri-orbital hematoma (OR\u2009=\u20092.5, p\u2009&lt;\u20090.001), epistaxis (OR\u2009=\u20094.1, p\u2009&lt;\u20090.001), subconjunctival ecchymosis (OR\u2009=\u20092.3, p\u2009=\u20090.02), and intra-oral hematoma (OR\u2009=\u20097.1, p\u2009&lt;\u20090.001) were significant fracture predictors. Among UA, peri-orbital hematoma (OR\u2009=\u20092.2, p\u2009=\u20090.04), epistaxis (OR\u2009=\u20095.4, p\u2009&lt;\u20090.001), subconjunctival ecchymosis (OR\u2009=\u20093.7, p\u2009=\u20090.008), and intra-oral hematoma (OR\u2009=\u200922.0, p\u2009&lt;\u20090.001) were significant fracture predictors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Maxillofacial haemorrhagic symptoms were observed more frequently in the UA group than in the NUA group. However, in both groups, maxillofacial haemorrhagic symptoms appear to be predictors of maxillofacial fractures. Caution is warranted in attributing these symptoms solely to antithrombotic use during emergency department assessments.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00068-023-02428-0","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T06:02:36Z","timestamp":1704866556000},"page":"543-550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Maxillofacial haemorrhagic symptoms in emergency department patients: impact of antithrombotics"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4980-5526","authenticated-orcid":false,"given":"Pieter Date","family":"van der Zaag","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Geurts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romke","family":"Rozema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge H. F.","family":"Reininga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baucke","family":"van Minnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"REDUCTION study group members","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"issue":"3","key":"2428_CR1","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1161\/CIRCRESAHA.118.313155","volume":"124","author":"NC Chan","year":"2019","unstructured":"Chan NC, Weitz JI. Antithrombotic agents. Circ Res. 2019;124(3):426\u201336. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.313155.","journal-title":"Circ Res"},{"key":"2428_CR2","unstructured":"Zorginstituut Nederland\/GIP. Zorginstituut Nederland\/ GIPdatabank. Aantal gebruikers 2016\u20132020 voor ATC-subgroep B01. 2023. https:\/\/www.gipdatabank.nl\/databank?infotype=g&label=00-totaal&tabel=B_01-basis&geg=gebr&item=B01. Accessed 12 Jan 2023."},{"key":"2428_CR3","unstructured":"World Health Organization (WHO). Number of persons aged 60 and over. 2022. https:\/\/platform.who.int\/data\/maternal-newborn-child-adolescent-ageing\/indicator-explorer-new\/mca\/number-of-persons-aged-over-60-years-or-over-(thousands). Accessed 12 Jan 2023."},{"issue":"7368","key":"2428_CR4","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1136\/bmj.325.7368.828","volume":"325","author":"DA Fitzmaurice","year":"2002","unstructured":"Fitzmaurice DA. ABC of antithrombotic therapy: bleeding risks of antithrombotic therapy. BMJ. 2002;325(7368):828\u201331. https:\/\/doi.org\/10.1136\/bmj.325.7368.828.","journal-title":"BMJ"},{"issue":"1","key":"2428_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.injury.2013.09.010","volume":"45","author":"A Somasundaram","year":"2014","unstructured":"Somasundaram A, Laxton AW, Perrin RG. The clinical features of periorbital ecchymosis in a series of trauma patients. Injury. 2014;45(1):203\u20135. https:\/\/doi.org\/10.1016\/j.injury.2013.09.010.","journal-title":"Injury"},{"key":"2428_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0194599819890327","volume":"162","author":"DE Tunkel","year":"2020","unstructured":"Tunkel DE, Anne S, Payne SC, et al. Clinical practice guideline: nosebleed (epistaxis). Otolaryngol Head Neck Surg. 2020;162:1. https:\/\/doi.org\/10.1177\/0194599819890327.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"1","key":"2428_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/003591571200501005","volume":"5","author":"F Coleman","year":"1912","unstructured":"Coleman F. An important sign in the diagnosis of fracture of the jaw. Proc R Soc Med. 1912;5(1):13\u20135. https:\/\/doi.org\/10.1177\/003591571200501005.","journal-title":"Proc R Soc Med"},{"issue":"10","key":"2428_CR8","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0020-1383(01)00144-9","volume":"32","author":"FAM Herbella","year":"2001","unstructured":"Herbella FAM, Mudo M, Delmonti C, Braga FM, Del Grande JC. \u2018Raccoon Eyes\u2019 (periorbital haematoma) as a sign of skull base fracture. Injury. 2001;32(10):745\u20137. https:\/\/doi.org\/10.1016\/S0020-1383(01)00144-9.","journal-title":"Injury"},{"issue":"4","key":"2428_CR9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.18869\/acadpub.beat.5.4.499","volume":"5","author":"BJ Phillips","year":"2017","unstructured":"Phillips BJ, Turco LM. Le fort fractures: a collective review. Bull Emerg Trauma. 2017;5(4):221\u201330. https:\/\/doi.org\/10.18869\/acadpub.beat.5.4.499.","journal-title":"Bull Emerg Trauma"},{"issue":"11","key":"2428_CR10","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00106-008-1838-3","volume":"56","author":"BJ Folz","year":"2008","unstructured":"Folz BJ, Kanne M, Werner JA. Aktuelle aspekte zur epistaxis. HNO. 2008;56(11):1157\u201366. https:\/\/doi.org\/10.1007\/s00106-008-1838-3.","journal-title":"HNO"},{"issue":"12","key":"2428_CR11","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.ijom.2012.09.024","volume":"42","author":"P Maurer","year":"2013","unstructured":"Maurer P, Conrad-Hengerer I, Hollstein S, Mizziani T, Hoffmann E, Hengerer F. Orbital haemorrhage associated with orbital fractures in geriatric patients on antiplatelet or anticoagulant therapy. Int J Oral Maxillofac Surg. 2013;42(12):1510\u20134. https:\/\/doi.org\/10.1016\/j.ijom.2012.09.024.","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"10","key":"2428_CR12","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.injury.2019.08.035","volume":"50","author":"BI Berg","year":"2019","unstructured":"Berg BI, Flury E, Thieringer FM, et al. Retrobulbar haematoma in the era of anticoagulants. Injury. 2019;50(10):1641\u20138. https:\/\/doi.org\/10.1016\/j.injury.2019.08.035.","journal-title":"Injury"},{"key":"2428_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00068-022-01968-1","author":"R Rozema","year":"2022","unstructured":"Rozema R, Moumni ME, de-Vries GT, et al. A clinical decision aid for patients with suspected midfacial and mandibular fractures (the REDUCTION-I study): a prospective multicentre cohort study. Eur J Trauma Emerg Surg. 2022. https:\/\/doi.org\/10.1007\/s00068-022-01968-1.","journal-title":"Eur J Trauma Emerg Surg"},{"issue":"Suppl 1","key":"2428_CR14","doi-asserted-by":"publisher","first-page":"S059","DOI":"10.1055\/S-0034-1389560","volume":"7","author":"C Kunz","year":"2014","unstructured":"Kunz C, Audig\u00e9 L, Cornelius CP, et al. The comprehensive AOCMF classification system: midface fractures\u2014level 2 tutorial. Craniomaxillofac Trauma Reconstr. 2014;7(Suppl 1):S059. https:\/\/doi.org\/10.1055\/S-0034-1389560.","journal-title":"Craniomaxillofac Trauma Reconstr"},{"key":"2428_CR15","volume-title":"Surgery of Facial Fractures","author":"OD Reed","year":"1964","unstructured":"Reed OD, Paul N. Surgery of Facial Fractures. Philadelphia: W. B. Saunders; 1964."},{"issue":"7","key":"2428_CR16","doi-asserted-by":"publisher","first-page":"e211693","DOI":"10.1001\/jamahealthforum.2021.1693","volume":"2","author":"A Troy","year":"2021","unstructured":"Troy A, Anderson TS. National trends in use of and spending on oral anticoagulants among US medicare beneficiaries From 2011 to 2019. JAMA Health Forum. 2021;2(7):e211693. https:\/\/doi.org\/10.1001\/jamahealthforum.2021.1693.","journal-title":"JAMA Health Forum"},{"issue":"4","key":"2428_CR17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jormas.2019.09.002","volume":"121","author":"M Brucoli","year":"2020","unstructured":"Brucoli M, Boffano P, Romeo I, et al. Epidemiology of maxillofacial trauma in the elderly: a European multicenter study. J Stomatol Oral Maxillofac Surg. 2020;121(4):330\u20138. https:\/\/doi.org\/10.1016\/j.jormas.2019.09.002.","journal-title":"J Stomatol Oral Maxillofac Surg"},{"issue":"5","key":"2428_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/J.JEMERMED.2016.05.045","volume":"51","author":"JM Chauny","year":"2016","unstructured":"Chauny JM, Marquis M, Bernard F, et al. Risk of delayed intracranial hemorrhage in anticoagulated patients with mild traumatic brain injury: systematic review and meta-analysis. J Emerg Med. 2016;51(5):519\u201328. https:\/\/doi.org\/10.1016\/J.JEMERMED.2016.05.045.","journal-title":"J Emerg Med"},{"issue":"5","key":"2428_CR19","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jemermed.2021.04.017","volume":"61","author":"H Valiuddin","year":"2021","unstructured":"Valiuddin H, Calice M, Alam A, et al. Incidence of traumatic delayed intracranial hemorrhage among patients using direct oral anticoagulants. J Emerg Med. 2021;61(5):489\u201398. https:\/\/doi.org\/10.1016\/j.jemermed.2021.04.017.","journal-title":"J Emerg Med"},{"issue":"4","key":"2428_CR20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.4193\/Rhino16.040","volume":"54","author":"KM Musgrave","year":"2016","unstructured":"Musgrave KM, Powell J. A systematic review of anti-thrombotic therapy in epistaxis. Rhinol J. 2016;54(4):292\u2013391. https:\/\/doi.org\/10.4193\/Rhino16.040.","journal-title":"Rhinol J"},{"issue":"1","key":"2428_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1067\/moe.2003.10","volume":"95","author":"S Mahmood","year":"2003","unstructured":"Mahmood S, Lowe T. Management of epistaxis in the oral and maxillofacial surgery setting: an update on current practice. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol. 2003;95(1):23\u20139. https:\/\/doi.org\/10.1067\/moe.2003.10.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol"},{"issue":"5","key":"2428_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1749-4486.2007.01530.x","volume":"32","author":"TWM Walker","year":"2007","unstructured":"Walker TWM, Macfarlane TV, McGarry GW. The epidemiology and chronobiology of epistaxis: an investigation of Scottish hospital admissions 1995\u20132004. Clin Otolaryngol. 2007;32(5):361\u20135. https:\/\/doi.org\/10.1111\/j.1749-4486.2007.01530.x.","journal-title":"Clin Otolaryngol"},{"issue":"8","key":"2428_CR23","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s00405-018-5043-z","volume":"275","author":"AMS Buchberger","year":"2018","unstructured":"Buchberger AMS, Baumann A, Johnson F, et al. The role of oral anticoagulants in epistaxis. Eur Arch Otorhinolaryngol. 2018;275(8):2035\u201343. https:\/\/doi.org\/10.1007\/s00405-018-5043-z.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"3","key":"2428_CR24","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s11239-019-01824-x","volume":"47","author":"P Stankovic","year":"2019","unstructured":"Stankovic P, Georgiew R, Frommelt C, et al. Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon. J Thromb Thrombolysis. 2019;47(3):384\u201391. https:\/\/doi.org\/10.1007\/s11239-019-01824-x.","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"2428_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/coa.12904","volume":"43","author":"TC Sauter","year":"2018","unstructured":"Sauter TC, Hegazy K, Hautz WE, et al. Epistaxis in anticoagulated patients: fewer hospital admissions and shorter hospital stays on rivaroxaban compared to phenprocoumon. Clin Otolaryngol. 2018;43(1):103\u20138. https:\/\/doi.org\/10.1111\/coa.12904.","journal-title":"Clin Otolaryngol"},{"issue":"6","key":"2428_CR26","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.otoeng.2014.10.002","volume":"65","author":"FJ Garc\u00eda Callejo","year":"2014","unstructured":"Garc\u00eda Callejo FJ, B\u00e9cares Mart\u00ednez C, Calvo Gonz\u00e1lez J, Mart\u00ednez Beneyto P, Marco Sanz M, Marco AJ. Epistaxis and dabigatran, a new non-vitamin K antagonist oral anticoagulant. Acta Otorrinolaringol (Engl Ed). 2014;65(6):346\u201354. https:\/\/doi.org\/10.1016\/j.otoeng.2014.10.002.","journal-title":"Acta Otorrinolaringol (Engl Ed)"},{"issue":"2","key":"2428_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/coa.13898","volume":"47","author":"P Stankovi\u0107","year":"2022","unstructured":"Stankovi\u0107 P, Hoch S, Rudhart S, Obradovi\u0107 D, Dagres N, Wilhelm T. Direct oral anticoagulants versus vitamin K antagonists in epistaxis patients: a systematic review and meta-analysis. Clin Otolaryngol. 2022;47(2):255\u201363. https:\/\/doi.org\/10.1111\/coa.13898.","journal-title":"Clin Otolaryngol"},{"issue":"12","key":"2428_CR28","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.mayocp.2014.09.009","volume":"89","author":"V Abrich","year":"2014","unstructured":"Abrich V, Brozek A, Boyle TR, Chyou PH, Yale SH. Risk factors for recurrent spontaneous epistaxis. Mayo Clin Proc. 2014;89(12):1636\u201343. https:\/\/doi.org\/10.1016\/j.mayocp.2014.09.009.","journal-title":"Mayo Clin Proc"},{"key":"2428_CR29","doi-asserted-by":"publisher","first-page":"101049","DOI":"10.1016\/j.ajoc.2021.101049","volume":"22","author":"AM Philip","year":"2021","unstructured":"Philip AM, Fry MV, Hermanson ME, Kelly LD. Massive spontaneous subconjunctival hemorrhage in a patient on therapeutic warfarin: a case report. Am J Ophthalmol Case Rep. 2021;22:101049. https:\/\/doi.org\/10.1016\/j.ajoc.2021.101049.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"1","key":"2428_CR30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1752-1947-6-105","volume":"6","author":"A Puri","year":"2012","unstructured":"Puri A, Nusrath MA, Harinathan D, Lyall J. Massive sublingual hematoma secondary to anticoagulant therapy complicated by a traumatic denture: a case report. J Med Case Rep. 2012;6(1):105. https:\/\/doi.org\/10.1186\/1752-1947-6-105.","journal-title":"J Med Case Rep"},{"issue":"13","key":"2428_CR31","doi-asserted-by":"publisher","first-page":"e1143","DOI":"10.1212\/WNL.0000000000005207","volume":"90","author":"R Kurogi","year":"2018","unstructured":"Kurogi R, Nishimura K, Nakai M, et al. Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin. Neurology. 2018;90(13):e1143\u20139. https:\/\/doi.org\/10.1212\/WNL.0000000000005207.","journal-title":"Neurology"},{"issue":"4","key":"2428_CR32","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/bloodadvances.2020003560","volume":"5","author":"JP Bassand","year":"2021","unstructured":"Bassand JP, Virdone S, Badoz M, et al. Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. Blood Adv. 2021;5(4):1081\u201391. https:\/\/doi.org\/10.1182\/bloodadvances.2020003560.","journal-title":"Blood Adv"},{"issue":"11","key":"2428_CR33","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1107039.","journal-title":"N Engl J Med"},{"issue":"12","key":"2428_CR34","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","volume":"124","author":"N van Es","year":"2014","unstructured":"van Es N, Coppens M, Schulman S, Middeldorp S, B\u00fcller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124(12):1968\u201375. https:\/\/doi.org\/10.1182\/blood-2014-04-571232.","journal-title":"Blood"},{"issue":"4","key":"2428_CR35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/medicines6040103","volume":"6","author":"S Kustos","year":"2019","unstructured":"Kustos S, Fasinu P. Direct-acting oral anticoagulants and their reversal agents\u2014an update. Medicines. 2019;6(4):103. https:\/\/doi.org\/10.3390\/medicines6040103.","journal-title":"Medicines"},{"issue":"9","key":"2428_CR36","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.repce.2021.07.002","volume":"40","author":"C Br\u00edzido","year":"2021","unstructured":"Br\u00edzido C, Ferreira AM, Lopes P, et al. Medication adherence to direct anticoagulants in patients with non-valvular atrial fibrillation\u2014a real world analysis. Rev Portuguesa Cardiol (Engl Ed). 2021;40(9):669\u201375. https:\/\/doi.org\/10.1016\/j.repce.2021.07.002.","journal-title":"Rev Portuguesa Cardiol (Engl Ed)"},{"issue":"1","key":"2428_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11096-014-0038-3","volume":"37","author":"WW Nelson","year":"2015","unstructured":"Nelson WW, Wang L, Baser O, Damaraju CV, Schein JR. Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation. Int J Clin Pharm. 2015;37(1):53\u20139. https:\/\/doi.org\/10.1007\/s11096-014-0038-3.","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"2428_CR38","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12959-016-0088-y","volume":"14","author":"JR Schein","year":"2016","unstructured":"Schein JR, White CM, Nelson WW, Kluger J, Mearns ES, Coleman CI. Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. Thromb J. 2016;14(1):14. https:\/\/doi.org\/10.1186\/s12959-016-0088-y.","journal-title":"Thromb J"},{"issue":"5","key":"2428_CR39","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1182\/blood-2018-06-820746","volume":"133","author":"S Piran","year":"2019","unstructured":"Piran S, Schulman S. Treatment of bleeding complications in patients on anticoagulant therapy. Blood. 2019;133(5):425\u201335. https:\/\/doi.org\/10.1182\/blood-2018-06-820746.","journal-title":"Blood"},{"key":"2428_CR40","volume-title":"Low-molecular-weight heparin (LMWH)","author":"F Solari","year":"2023","unstructured":"Solari F, Varacallo M. Low-molecular-weight heparin (LMWH). New York: Springer; 2023."}],"container-title":["European Journal of Trauma and Emergency Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00068-023-02428-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00068-023-02428-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00068-023-02428-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T07:04:37Z","timestamp":1713769477000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00068-023-02428-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2428"],"URL":"https:\/\/doi.org\/10.1007\/s00068-023-02428-0","relation":{},"ISSN":["1863-9933","1863-9941"],"issn-type":[{"type":"print","value":"1863-9933"},{"type":"electronic","value":"1863-9941"}],"subject":[],"published":{"date-parts":[[2024,1,10]]},"assertion":[{"value":"4 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Pieter Date van der Zaag, Stephanie Geurts, Romke Rozema, Inge H.F. Reininga, Baucke van Minnen and the REDUCTION study group members declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in compliance with the Declaration of Helsinki and the FEDERA (Foundation Federation of Dutch Medical Scientific Societies) code of conduct.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}